Advances in Virology,
Journal Year:
2024,
Volume and Issue:
2024(1)
Published: Jan. 1, 2024
The
omicron
variant
and
its
sublineages
are
highly
contagious,
they
still
constitute
a
global
source
of
concern
despite
vaccinations.
Hospitalizations
mortality
rates
resulting
from
infections
by
these
variants
common.
existing
therapeutic
alternatives
have
presented
various
setbacks
such
as
low
potency,
poor
pharmacokinetic
profiles,
drug
resistance.
need
for
alternative
options
cannot
be
overemphasized.
Plants
their
phytochemicals
present
interesting
characteristics
that
make
them
suitable
candidates
the
development
antiviral
agents.
This
study
aimed
to
investigate
potential
Imperata
cylindrica
(
I.
).
Specifically,
objective
this
was
identify
display
inhibitory
effects
against
SARS‐CoV‐2
main
protease
(M
pro
),
conserved
protein
among
coronaviruses.
Molecular
docking
in
silico
assays
were
used
assess
72
phytocompounds
found
ligands
M
(6LU7)
target.
Only
eight
(bifendate,
cylindrene,
tabanone,
siderin,
5‐hydroxy‐2‐[2‐(2‐hydroxyphenyl)ethyl]‐4H‐1‐benzopyran‐4‐one,
maritimin,
5‐methoxyflavone,
flavone)
displayed
high
binding
affinities
with
scores
ranging
−5.6
kcal/mol
−9.1
kcal/mol.
toxicological
revealed
tabanone
best
safest
phytochemical
an
agent
coronavirus
protease.
Thus,
served
baseline
further
vitro
vivo
assessment
validate
findings.
Expert Review of Clinical Pharmacology,
Journal Year:
2024,
Volume and Issue:
17(11), P. 1071 - 1079
Published: Sept. 26, 2024
This
study
aimed
to
establish
population
pharmacokinetics
(PPK)
models
of
nirmatrelvir/ritonavir
in
critically
ill
Chinese
patients
with
the
coronavirus
disease
2019
(COVID-19)
infection,
explore
factors
affecting
(PK)
nirmatrelvir/ritonavir.
Expert Review of Anti-infective Therapy,
Journal Year:
2024,
Volume and Issue:
unknown, P. 1 - 9
Published: Oct. 18, 2024
To
investigate
the
effectiveness
of
oral
antiviral
agents
-
nirmatrelvir
ritonavir
or
molnupiravir
in
non-hospitalized
COVID-19
patients
aged
<
60
years.
